Preclinical Evaluation of Intermediate Endpoints


NIH 2000 N01 CN	Study of Prostatic Intraepithelial Neoplasia Pezzuto, James M. / University of Illinois at Chicago	$109,077
NIH 2000 N01 CN	Preclinical Evaluation of Intermediate Endpoints Pezzuto, James M. / University of Illinois at Chicago	$32,702
NIH 1998 N01 CN	Preclinical Evaluation of Intermediate Endpoints Mehta, Rajendra G. / University of Illinois at Chicago
NIH 1997 N01 CN	Preclinical Evaluation of Intermediate Endpoints Das Gupta, Tapas K. / University of Illinois at Chicago
NIH 1996 N01 CN	Preclinical Evaluation of Intermediate Endpoints Das Gupta, T. / University of Illinois at Chicago
NIH 1995 N01 CN	Preclinical Evaluation of Intermediate Endpoints Das Gupta, T. / University of Illinois at Chicago
NIH 1994 N01 CN	Preclinical Evaluation of Intermediate Endpoints Moon, R. / University of Illinois at Chicago
NIH 1992 N01 CN	Preclinical Evaluation of Intermediate Endpoints and Das Gupta, T. / University of Illinois at Chicago

Christov, Konstantin T; Moon, Richard C; Lantvit, Daniel D et al. (2002) 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats. Cancer Res 62:5178-82

Kosmeder 2nd, J W; Pezzuto, J M (2001) Intermediate biomarkers. Cancer Treat Res 106:31-61